Urea Cycle Disorders Clinical Trial
Official title:
A Phase 2, Open-Label, Switch-Over, Dose-Escalation Study of the Safety and Tolerability of HPN-100 Compared to Buphenyl® (Sodium Phenylbutyrate) in Patients With Urea Cycle Disorders
The purpose of this study is to determine whether HPN-100 is safe and tolerable in subjects with Urea Cycle Disorders.
When protein is broken down in the body, nitrogen is formed. In healthy individuals, the body combines this nitrogen with other molecules to create a harmless substance called urea, which is excreted in the urine. Patients with Urea Cycle Disorders (UCD) are unable to create as much urea from nitrogen, and therefore, toxic levels of nitrogen can accumulate in the body, causing harm. To treat these patients, doctors usually have the patient consume less protein and supplement certain amino acids that may be lacking. A drug called Buphenyl® is sometimes prescribed as an adjunctive treatment for the chronic maintenance of UCD patients in order to keep ammonia levels down. Some issues with Buphenyl® include a high pill burden (up to 40 pills per day), bad taste and odor, and high sodium content. Like Buphenyl®, HPN-100 provides an alternate way for the body to dispose of nitrogen, other than through the urea cycle. Unlike Buphenyl®, HPN-100 is an odorless, tasteless, concentrated oil that does not contain large amounts of sodium. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02252770 -
Nitric Oxide Supplementation in Argininosuccinic Aciduria
|
N/A | |
Completed |
NCT01002469 -
Study to Evaluate 13 C Isotope Ratio Measurement for Urea Cycle Capacity Assessment
|
N/A | |
Completed |
NCT00986895 -
A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group
|
Phase 1 | |
Completed |
NCT01257737 -
To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)
|
Phase 4 | |
Recruiting |
NCT05671666 -
Ureagenesis Analysis in Healthy Subjects and in Urea Cycle Disorder Patients
|
N/A | |
Completed |
NCT02311283 -
Pilot Study: Urea Cycle Disorders Practice Patterns and Outcomes Assessment
|
N/A | |
Completed |
NCT02489292 -
Study to Evaluate the Efficacy of HepaStem in Urea Cycle Disorders Paediatric Patients (HEP002)
|
Phase 2 | |
Completed |
NCT00992459 -
Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders
|
Phase 3 | |
Completed |
NCT00947297 -
Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)
|
Phase 3 | |
Completed |
NCT02740153 -
PCORI Urea Cycle Disorder Study
|
||
Completed |
NCT02051049 -
Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001)
|
||
Completed |
NCT01765283 -
Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN)
|
Phase 1/Phase 2 | |
Completed |
NCT00947544 -
Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders
|
Phase 2 | |
Completed |
NCT01347073 -
Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)
|
Phase 3 | |
Completed |
NCT00718627 -
Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders
|
Phase 2 | |
Completed |
NCT03797131 -
Clinical Food Study to Evaluate the Effect of KB195 on Gut Nitrogen Metabolism in Patients With Urea Cycle Disorders
|
N/A | |
Completed |
NCT01549015 -
Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD) and Carriers of UCD Mutations to Evaluate Urea Cycle Function
|
N/A | |
Terminated |
NCT01541722 -
Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders
|
N/A | |
Completed |
NCT00345605 -
Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder
|
Phase 2 | |
Recruiting |
NCT00237315 -
Longitudinal Study of Urea Cycle Disorders
|